BridgeBio Pharma (BBIO) Asset Utilization Ratio (2021 - 2026)

BridgeBio Pharma has reported Asset Utilization Ratio for 6 years, with the latest figure at 0.5 in Q1 2026.

• Quarterly Asset Utilization Ratio rose 255.33% year-over-year to 0.5 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.5 (up 255.33% YoY) and the FY2025 annual result came in at 0.54, up 78.74% from the prior year.
• Asset Utilization Ratio eased to 0.5 in Q1 2026 per BBIO's latest filing, from 0.52 in the prior quarter.
• Over five years, Asset Utilization Ratio peaked at 0.52 in Q4 2025 and troughed at 0.01 in Q2 2023.
• A 5-year average of 0.2 and a median of 0.14 in 2025 frame the typical range for Asset Utilization Ratio.
• The sharpest annual moves came in 2023 and 2024: Asset Utilization Ratio slumped 90.41% in 2023, then surged 2552.92% in 2024.
• Over 5 years, Asset Utilization Ratio stood at 0.11 in 2022, then slumped by 86.52% to 0.02 in 2023, then jumped by 1708.76% to 0.28 in 2024, then soared by 85.32% to 0.52 in 2025, then slipped by 3.15% to 0.5 in 2026.
• According to Business Quant data, Asset Utilization Ratio over the past three periods registered 0.5, 0.52, and 0.34 for Q1 2026, Q4 2025, and Q3 2025 respectively.